• The Effect of a Wearable Cueing Device on Freezing of Gait in Parkinson's Disease

  NCT02356536

  CompletedInterventionalPhase 1Updated Aug 14, 2017
• A System to Help With Freezing of Gait in Parkinson's Patients

  NCT07542743

  Not yet recruitingInterventionalNot ApplicableUpdated Apr 21, 2026
• Cue2Walk, Cost-effectiveness of Automated Freezing Detection and Provision of External Cues in Comparison to Usual Care in People With Parkinson's Disease

  NCT06416345

  RecruitingInterventionalNot ApplicableUpdated Mar 16, 2026
• Digital Wearable Walking Aid for Freezing of Gait in Parkinson´s Disease

  NCT03978507

  CompletedInterventionalNot ApplicableUpdated Nov 27, 2023
• Spinal Cord Stimulation for Freezing of Gait in Parkinson's Disease

  NCT06798844

  RecruitingInterventionalPhase 2Updated Feb 13, 2025
• Sensory Cues for Freezing in Parkinson's Disease

  NCT00322426

  Unknown statusInterventionalNot ApplicableUpdated Jun 23, 2006

ClinicalTrials.gov ID

NCT07675408

Lead Sponsor

Fortis Medical Devices LimitedINDUSTRY

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

60Estimated

Last Update Posted

Jun 30, 2026Actual

Start Date

Oct 2026Estimated

Primary Completion Date

Feb 2027Estimated

Completion Date

Feb 2027Estimated

Official Title

Validation of cueStim for Reduction of Freezing of Gait in Parkinson's Disease

Brief Summary

The goal of this clinical trial is to learn if the cueStim device can reduce the duration of freezing of gait (FoG) that occurs in patients with Parkinson's Disease. The study will compare two modes of operation of the cueStim device; both modes of operation use the same wearable device. The purpose of the study is to compare how the two modes affect symptoms across study participants. Because this is a research study, it is not yet known whether either mode reduces symptoms.

Participants will:

• Be randomized to one of the two modes available on the cueStim device
• Wear the device for 4 weeks as they go about their daily life
• Complete daily diary entries to document symptoms, falls and overall experience
• Check-in with the clinical site throughout participation
• Complete a final follow-up visit

Detailed Description

This is a prospective, randomized, double-blind, parallel group, multicenter, pivotal clinical trial to validate the use of cueStim for reduction of duration of FoG in Parkinson's patients.

Enrolled subjects will be randomized 1:1 to two different modes of treatment. All subjects will be blinded to the study hypothesis. The clinician will not be blinded; however, specialists who will evaluate the outcome will be blinded. Enrolled subjects will be provided with training on the device during a clinic visit, and phone support is available throughout the home treatment duration.

Study procedures / visits consists of:

• In-clinic Screening visit to ensure eligibility
• Baseline visit for device setup and training (may be combined with screening visit)
• "Home" (unsupervised at and out of the home) use of the device for four (4) weeks) as the patient goes about their daily life
• End-of-treatment Follow-up visit

The primary objective of this clinical investigation is to determine if one mode of treatment demonstrates superiority after four weeks of device use, in reducing the duration of FoG, while the device is being worn by patients with PD receiving medication.

• Parkinson's Disease With Freezing of Gait

• CueStim

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Age 60-90 years, inclusive
• Diagnosis of idiopathic PD, confirmed by a neurologist/Medical Doctor (MD), medical records, and verified during a post consent in-clinic evaluation by a trained MD
• Patients can walk 12 meters without a walking aid (cane permitted during daily life)
• The patient is using levodopa treatment. PD medications are stable, with no changes in PD-related medications for at least four weeks prior to screening visit, and stable dosing expected for duration of the study
• Score greater or equal to 22 on the Montreal Cognitive Assessment (MoCA)
• Satisfactory standard neurological examination, including completion of MDS- UPDRS I, II, III and IV by study clinician
• PTF ≥20% during the baseline in-clinic FoG Provocation Test (conducted without the device) as determined by the centralized blinded video analysis using the FoG Switch tool by trained personnel independent of site investigators.

Exclusion Criteria

• Atypical or secondary parkinsonism, including vascular parkinsonism
• History of dementia, severe depression, psychosis, or active hallucinations
• History of migraines, tinnitus, seizures or sensory issues
• Other neurological or orthopedic impairment significantly affecting gait
• Previous use of cueing devices within the last 3 months
• Use of implanted electronic devices, including deep brain stimulation (DBS)
• Use of assistive devices incompatible with the device (DBS users will be excluded
• Is participating in another clinical trial during the study period
• Any condition that, in the investigator's opinion, makes the participant unsuitable
• As per medical records, any of the following identified within 3 months: myocardial infarction, hospitalization for unstable angina, stroke, coronary artery bypass graft, percutaneous coronary intervention, implantation or use of a cardiac resynchronization therapy device, active treatment for cancer or other malignant disease, uncontrolled congestive heart disease (NYHA class >3), acute psychosis or major psychiatric disorders or continued substance abuse.
• Pregnant or breastfeeding women

Primary Purpose

Supportive Care

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Double

Lead Sponsor

Fortis Medical Devices LimitedINDUSTRY

Collaborators

AvaniaINDUSTRY

j.lucas.mckay@emory.edu404-550-5157